Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Chest

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/chest.11-2672PMID 22383668PMCID PMC3435140
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

  2011cited by this paper
• Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

  2010cited by this paper
• Cystic Fibrosis

  2009cited by this paper
• Does the Macroduct collection system reliably define sweat chloride concentration in subjects with intermediate results?

  2009cited by this paper
• Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

  2009cited by this paper
• Identification of the Cystic Fibrosis Gene : Chromosome Walking and Jumping Author ( s ) :

  2008cited by this paper
• Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.

  2006cited by this paper
• Cystic fibrosis.

  2005cited by this paper
• Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis.

  2005cited by this paper
• Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study.

  2003cited by this paper
• Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening

  2002cited by this paper
• Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings.

  2001cited by this paper
• Standardization of Spirometry, 1994 Update. American Thoracic Society.

  1995cited by this paper
• Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

  1994cited by this paper
• Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype.

  1994cited by this paper
• Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland.

  1992cited by this paper
• Mislocalization of ΔF508 CFTR in cystic fibrosis sweat gland

  1992cited by this paper
• Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive

  1992cited by this paper
• Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA

  1989cited by this paper
• Identification of the cystic fibrosis gene: chromosome walking and jumping.

  1989cited by this paper
• Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

  1989cited by this paper
• Identification of the cystic fibrosis gene: genetic analysis.

  1989cited by this paper
• Identification of the cystic fibrosis gene: genetic analysis

  1989cited by this paper

• Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.

  2026cites this paper
• EPIDEMIOLOGY AND GENETIC ASPECTS OF CYSTIC FIBROSIS (LITERATURE REVIEW)

  2025cites this paper
• Cystic fibrosis therapy: from symptoms to the cause of the disease

  2025cites this paper
• The new triple CFTR modulator vanzacaftor/tezacaftor/ deutivacaftor (Aliftrek®) and its place in the treatment of cystic fibrosis

  2025cites this paper
• Cystic Fibrosis Treatment Landscape: Progress, Challenges, and Future Directions

  2025cites this paper
• Efficacy of Trikafta (ELX/TEZ/IVA) & Symdeko (TEZ/IVA) in Treating Cystic Fibrosis with F508del Allele: A Systematic Review and Meta-analysis

  2025cites this paper
• Impacts and New Challenges with Highly Effective Modulator Therapies in Younger Children with Cystic Fibrosis

  2025cites this paper
• Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysis

  2025cites this paper
• Chronic pancreatitis patient-derived organoids reveal new paths to precision therapeutics

  2025cites this paper
• Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.

  2025cites this paper
• Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

  2024cites this paper
• Diagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?

  2024cites this paper
• Systematic review on the safety of the use of quinolones in the pediatric population

  2024cites this paper
• Moduladores de la conductancia de transmembrana de fibrosis quística y nuevos tratamientos para fibrosis quística

  2024cites this paper
• Cutaneous Manifestations of Cystic Fibrosis.

  2024cites this paper
• Pathogenesis and symptomatic therapy of cystic fibrosis

  2024cites this paper
• Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies.

  2024cites this paper
• A rapid LC-MS/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma.

  2024cites this paper
• Lessons from other fields of medicine, Part 2: Cystic fibrosis.

  2023cites this paper
• FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.

  2023cites this paper
• [The Impact of CFTR Modulating Therapy on Chronic Lung Infection in Patients with Cystic Fibrosis].

  2023cites this paper
• The gut-lung axis in the CFTR modulator era

  2023cites this paper
• Cystic Fibrosis Transmembrane Conductance Regulator Protein Modulators in Children and Adolescents with different CF Genotypes - Systematic Review and Meta-Analysis.

  2023cites this paper
• Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis.

  2023cites this paper
• Cystic Fibrosis: A Review.

  2023cites this paper
• Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators

  2023cites this paper
• Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.

  2023cites this paper
• CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes

  2023cites this paper
• CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis.

  2023cites this paper
• CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018

  2022cites this paper
• Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis

  2022cites this paper
• The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis

  2022cites this paper
• CFTR Modulators: Current Status and Evolving Knowledge

  2022cites this paper
• Trends in Growth and Maturation in Children with Cystic Fibrosis Throughout Nine Decades

  2022cites this paper
• New drugs in cystic fibrosis: what has changed in the last decade?

  2022cites this paper
• Assessment of Cystic Fibrosis Distribution Based on Air Pollution by Geographical Information System (GIS)

  2022cites this paper
• FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis Genotypes

  2022cites this paper
• Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.

  2022cites this paper
• Cystic Fibrosis: Highly Effective Targeted Therapeutics and the Impact on Sex and Racial Disparities.

  2022cites this paper
• Perspectives on Genetic Medicine for Cystic Fibrosis.

  2022cites this paper
• Problems and achievements in the study of clinical and genetic aspects of cystic fibrosis

  2022cites this paper
• Similarity-Principle-Based Machine Learning Method for Clinical Trials and Beyond

  2022cites this paper
• CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France

  2022cites this paper
• Cystic Fibrosis Modulator Therapies.

  2022cites this paper
• Emerging medicines to improve the basic defect in cystic fibrosis

  2022cites this paper
• Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy

  2021cites this paper
• The Distribution and Role of the CFTR Protein in the Intracellular Compartments

  2021cites this paper
• S-nitrosothiols signaling in cystic fibrosis airways

  2021cites this paper
• The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.

  2021cites this paper
• State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy

  2021cites this paper
• New Therapies to Correct the Cystic Fibrosis Basic Defect

  2021cites this paper
• Cystic Fibrosis in 2021: "The Times They Are A-Changin".

  2021cites this paper
• Inhibition of Pseudomonas aeruginosa Alginate Synthesis by Ebselen Oxide and Its Analogues.

  2021cites this paper
• Systems Biology and Bile Acid Signalling in Microbiome-Host Interactions in the Cystic Fibrosis Lung

  2021cites this paper
• Changes in the Cystic Fibrosis Airway Microbiome in Response to CFTR Modulator Therapy

  2021cites this paper
• Modulation of Ion Transport to Restore Airway Hydration in Cystic Fibrosis

  2021cites this paper
• Pharmacogenomics in the era of next generation sequencing – from byte to bedside

  2021cites this paper
• Next-Generation Sequencing for Molecular Diagnosis of Cystic Fibrosis in a Brazilian Cohort

  2021cites this paper
• Modulators of CFTR. Updates on clinical development and future directions.

  2021cites this paper
• Cystic Fibrosis Human Organs-on-a-Chip

  2021cites this paper
• Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches

  2021cites this paper
• Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry.

  2021cites this paper
• Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.

  2021cites this paper
• Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

  2021cites this paper
• Improvement of Pulmonary Function in Cystic Fibrosis Patients following Endoscopic Sinus Surgery

  2021cites this paper
• Cystic fibrosis – Ten promising therapeutic approaches in the current era of care

  2020cites this paper
• Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis

  2020cites this paper
• Epithelial vectorial ion transport in cystic fibrosis: Dysfunction, measurement, and pharmacotherapy to target the primary deficit

  2020cites this paper
• Treating Cystic Fibrosis with mRNA and CRISPR

  2020cites this paper
• The Scientific and Lay Narratives

  2020cites this paper
• Targeting the Underlying Defect in CFTR with Small Molecule Compounds

  2020cites this paper
• Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey

  2020cites this paper
• Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review.

  2020cites this paper
• From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis

  2020cites this paper
• Chapter 23: Respiratory: Ivacaftor/CFTR Case

  2020cites this paper
• The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis

  2020cites this paper
• Overview of CFTR Modulators and Gene Therapy

  2020cites this paper
• Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function.

  2020cites this paper
• Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease

  2020cites this paper
• CFTR and Cystic Fibrosis: A Need for Personalized Medicine

  2020cites this paper
• Preface 2 – Enter Patient

  2020cites this paper
• The Evolution of Precision Medicine in Cystic Fibrosis

  2020cites this paper
• The Hypothesis That Refuses to Die

  2020cites this paper
• Guideline

  2020cites this paper
• Protein Paradox

  2020cites this paper
• Biomarkers: The Promise and the Fallacy

  2020cites this paper
• Note Added at Press Time – Reviving LOF

  2020cites this paper
• Predictions for the 2020s and Beyond

  2020cites this paper
• The Fault in Our Models

  2020cites this paper
• The Shaky Six and the “Second Reality”

  2020cites this paper
• Review of Rapid Advances in Cystic Fibrosis.

  2020cites this paper
• Preface 1 – The Question

  2020cites this paper
• Index

  2020cites this paper
• Our Living Dissonance

  2020cites this paper
• Molecular Physiology and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator

  2020cites this paper
• The Moonshot: Population-Based Studies of Aging

  2020cites this paper
• Lessons from Oncology

  2020cites this paper
• Re-imagining cystic fibrosis care: next generation thinking

  2020cites this paper
• References

  2020cites this paper
• Pieces of a Puzzle?

  2020cites this paper